688298.SS
688298.SS
CNE100003RM8
ZHEJIANG ORIENT GENE BIOTECH CO
Loading chart...

Company Profile

Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products in China and internationally. Its products include POCT instant diagnostic reagents that are used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company also offers human and animal health products; and raw materials for rapid testing, fluorescent immunoassay, western blot, biochemistry, and molecular diagnostics. It serves pharmacies chain, supermarkets, tertiary hospitals, healthcare institutions, third-party laboratories, medical distributors, and pharmaceutical distribution clients. Zhejiang Orient Gene Biotech Co., Ltd was incorporated in 2005 and is based in Huzhou, China.

Related stocks

300482.SZ
300482.SZ • China
WONDFO BIOTECH
16.74 CNY
1.17B USD 1Y -22%
2697.HK
2697.HK • China
TH MEDICAL-B
183 HKD
1.2B USD
300206.SZ
300206.SZ • China
EDAN
11.68 CNY
1.01B USD 1Y -4.1%
301367.SZ
301367.SZ • China
BMC
46.71 CNY
875.66M USD 1Y -20.4%
2675.HK
2675.HK • China
EDGE MEDICAL-B
33 HKD
1.64B USD
1302.HK
1302.HK • China
LIFETECH SCI
1.35 HKD
757.09M USD 1Y -36.9%
688626.SS
688626.SS • China
XIANGYU MEDICAL CO LTD
40.49 CNY
969.39M USD 1Y -22.7%
2190.HK
2190.HK • China
ZYLOXTB
20.5 HKD
861.68M USD 1Y -17.1%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
51.5% p.a.
Max Drawdown (5Y)
-92.9%
Sharpe Ratio (5Y)
-0.55
Beta Factor
0.82
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (51.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -92.9% in the extended horizon.
ende